Navigation Links
Anthera Announces Third Quarter 2011 Financial Report and Conference Call
Date:10/24/2011

HAYWARD, Calif., Oct. 24, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it will release its third quarter 2011 financial report and provide an update on its development programs after market close on Tuesday, November 1, 2011.  Anthera will host a conference call at 5 pm Eastern Time in conjunction with the release.Conference Call Access:Date:

November 1, 2011Time:

5:00 pm Eastern TimeDomestic Dial-in:

(877) 312-8807International Dial-in:

(253) 237-1190Conference ID:

22066672To access the 24-hour audio replay, U.S. and Canadian participants may dial (855) 859-2056; international participants may dial (404) 537-3406.  The conference ID for the replay is 22066672. The audio replay will be available until November 8, 2011.  

About Anthera PharmaceuticalsAnthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases.  Anthera has three late stage clinical products: varespladib methyl (A-002), A-001 and blisibimod (A-623).  Varespladib methyl (A-002) and A-001 are designed to inhibit a novel enzyme target known as secretory phospholipase A2 (sPLA2).  Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease.  Blisibimod targets elevated levels of B-lymphocyte stimulator (BAFF), which have been associated with a variety of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus (lupus) and rheumatoid arthritis.  

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or 510-856-5586.


'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
2. Anthera Pharmaceuticals to Present at the Citi 2011 Global Health Care Conference
3. Anthera Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results and Operational Update
4. Anthera Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
5. Anthera Pharmaceuticals Promotes Colin Hislop, M.D., to Chief Medical Officer
6. Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial
7. Antheras Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease
8. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
9. Spherix Announces Results from New Preclinical Studies Showing SPX-106T Produces Significant Reductions in Cholesterol, Fat Deposition and Body Weight
10. Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2011 Financial Results Webcast and Conference Call
11. Omega Protein Announces Retention of Lipid Technologies, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... , ... July 20, 2017 , ... Corporate Directors Forum ... its 27th annual Director of the Year Awards. , The awards will be presented ... This annual event celebrates directors who have made significantly positive contributions in the ...
(Date:7/18/2017)... ... July 18, 2017 , ... Genedata, a leading ... science and technology company, has implemented Genedata Biologics ™ to scale-up their ... Oncology, Immunology, and Neurodegenerative Diseases. , The need to systematically evaluate large panels ...
(Date:7/18/2017)... ... July 18, 2017 , ... Recently recognized by ... ) announces the migration of its flagship cloud-based product Planet Life Cycle – ... enterprise work management system that merges strategic and financial planning with execution. The ...
(Date:7/17/2017)... ... July 17, 2017 , ... OHAUS ... announced the launch of its new line of Heavy-Duty Orbital Shakers today. , ... analog and digital) for laboratory applications. These shakers are ideal for load ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
Breaking Biology News(10 mins):